These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29150066)

  • 1. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 2. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria.
    Santiago L; Ferreira B; Ramos L; Gonçalo M
    Br J Dermatol; 2019 Jan; 180(1):199-200. PubMed ID: 30007073
    [No Abstract]   [Full Text] [Related]  

  • 3. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
    Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
    Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
    Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.
    Cugno M; Asero R; Ferrucci S; Lorini M; Carbonelli V; Tedeschi A; Marzano AV
    Allergy; 2018 Dec; 73(12):2408-2411. PubMed ID: 30076634
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
    Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
    J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
    [No Abstract]   [Full Text] [Related]  

  • 7. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
    Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
    Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab use during pregnancy for CIU: a tertiary care experience.
    Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
    Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
    Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
    J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
    Sánchez J; Alvarez L; Cardona R
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
    Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
    J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(4):364-366. PubMed ID: 36314621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(5):364-366. PubMed ID: 36314703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.